Intestinal Microbiota: The Driving Force behind Advances in Cancer Immunotherapy

SIMPLE SUMMARY: Despite the great achievements of cancer immunotherapy in a variety of tumors, tumor heterogeneity and drug resistance still plague patients and clinical researchers. In particular, the occurrence of immune-related adverse events forces patients to discontinue cancer immunotherapy. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Zhujiang, Fu, Jihong, Peng, Xiang, Tang, Dong, Song, Jinglue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564057/
https://www.ncbi.nlm.nih.gov/pubmed/36230724
http://dx.doi.org/10.3390/cancers14194796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564057/
https://www.ncbi.nlm.nih.gov/pubmed/36230724
http://dx.doi.org/10.3390/cancers14194796

Ejemplares similares